Subscribe to the News-Journal RSS Feed Mobile Access E-Newsletter Log In or Register as a New User 
Classifieds
Automotive
Real Estate
Employment
Merchandise
HEALTH
HealthDay | Archives

Omnaris Approved for Hay Fever
Related News from HealthDay
FDA Touts Efforts to Enhance Food Safety
Study Calls for Greater Scrutiny of ’Off-Label’ Drug Use
Promacta Approved for Rare Blood Disorder
An Allergy Checklist for Holiday Gatherings
Banzel Approved for Lennox-Gastaut Syndrome
Health News Archives
   

Omnaris Approved for Hay Fever

MONDAY, Oct. 23 (HealthDay News) -- Omnaris (ciclesonide) nasal spray has been approved by the U.S. Food and Drug Administration to treat symptoms of allergic rhinitis, commonly known as hay fever.

The drug, approved for adults and children 12 years and older, is a corticosteroid that suppresses the body's immune response to the allergens that trigger hay fever.

Some 35 million Americans have hay fever, making it the most common allergic condition, the FDA said. Symptoms include runny and itchy nose, sneezing, and nasal congestion.

During clinical testing, people who took Omnaris had up to a 10 percent reduction in nasal symptoms, compared with those who took a non-medicinal placebo. The most common side effects reported were headache, nosebleed, and nasal inflammation.

Omnaris is manufactured by Altana Pharma U.S., Inc.

More information

Visit the National Library of Medicine to learn more about hay fever.

 

Copyright © 2006 ScoutNews, LLC. All rights reserved.



HELPFUL TOOLS

Analyze Yourself

Calculate your body mass.
Analyze yourself for depression.
Rate yourself for thyroid disease.
Do you have a sinus infection?



 

Nacogdoches News | Nacogdoches Weather | Sports | Life | Business News | Opinions | Classifieds | Sitemap
Nacogdoches Cars | Nacogdoches Real Estate | Nacogdoches Jobs

Copyright 2008 The Daily Sentinel. All rights reserved. - The Daily Sentinel - Our Partners

By using this service, you accept the terms of our visitor agreement and privacy policy.
Registered site users, you may edit your profile.
Having trouble? Visit our help & FAQ.